Overview

Immune Modulation by Misoprostol

Status:
Completed

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

The present study is designed to address the null hypothesis that there is no difference in the local and systemic immunomodulatory effects of buccally or vaginally administered misoprostol in healthy, reproductive-age women.

Phase:

Early Phase 1

Details

Lead Sponsor:

Vanderbilt University

Collaborator:

Gynuity Health Projects

Treatments:

Misoprostol